Healthcare -
Biotechnology - NASDAQ - US
$ 2.8
-0.351 %
$ 106 M
Market Cap
-1.71
P/E
1. INTRINSIC VALUE
Balance Sheet
Orchestra BioMed Holdings, Inc.
| Current Assets | 69.2 M |
| Cash & Short-Term Investments | 66.8 M |
| Receivables | 92 K |
| Other Current Assets | 2.27 M |
| Non-Current Assets | 7 M |
| Long-Term Investments | 2.5 M |
| PP&E | 3.49 M |
| Other Non-Current Assets | 1.02 M |
| Current Liabilities | 16.2 M |
| Accounts Payable | 5.13 M |
| Short-Term Debt | 550 K |
| Other Current Liabilities | 10.5 M |
| Non-Current Liabilities | 27 M |
| Long-Term Debt | 1.69 M |
| Other Non-Current Liabilities | 25.3 M |
EFFICIENCY
Earnings Waterfall
Orchestra BioMed Holdings, Inc.
| Revenue | 2.64 M |
| Cost Of Revenue | 204 K |
| Gross Profit | 2.43 M |
| Operating Expenses | 66.7 M |
| Operating Income | -64.3 M |
| Other Expenses | -3.28 M |
| Net Income | -61 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Orchestra BioMed Holdings, Inc.
| Net Income | -61 M |
| Depreciation & Amortization | 308 K |
| Capital Expenditures | -289 K |
| Stock-Based Compensation | 10.6 M |
| Change in Working Capital | -765 K |
| Others | -3.42 M |
| Free Cash Flow | -50.8 M |
Wall Street Analysts Price Targets
Orchestra BioMed Holdings, Inc.
Wall Street analysts predict an average 1-year price target for OBIO of $12 , with forecasts ranging from
a
low of
$12 to a high of $12 .
OBIO Lowest Price Target
Wall Street Target
12 USD
328.57%
OBIO Average Price Target
Wall Street Target
12 USD
328.57%
OBIO Highest Price Target
Wall Street Target
12 USD
328.57%
4. DIVIDEND
ANALYSIS
OBIO does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Orchestra BioMed Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
226 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
48 K USD 2
3-6 MONTHS
62.5 K USD 1
6-9 MONTHS
59.9 K USD 2
9-12 MONTHS
7. News
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy.
globenewswire.com
- 1 week ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.
zacks.com
- 1 month ago
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update.
globenewswire.com
- 1 month ago
Orchestra BioMed to Present at Upcoming Investor Conferences
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.
globenewswire.com
- 2 months ago
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio.
globenewswire.com
- 2 months ago
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
globenewswire.com
- 2 months ago
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach.
globenewswire.com
- 2 months ago
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.
globenewswire.com
- 5 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.38 per share a year ago.
zacks.com
- 5 months ago
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update.
globenewswire.com
- 5 months ago
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.35 per share a year ago.
zacks.com
- 8 months ago
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.
globenewswire.com
- 8 months ago
8. Profile
Summary
Orchestra BioMed Holdings, Inc. OBIO
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 106 M
Dividend Yield
0.00%
Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Contact
150 Union Square Drive, New Hope, PA, 18938
https://orchestrabiomed.com
IPO
Date
Aug. 4, 2020
Employees
70
Officers
Mr. David P. Hochman
Founder, Chairman of the Board of Directors & Chief Executive Officer
Mr. Andrew Lawrence Taylor M.B.A.
Chief Financial Officer
Mr. William Reed Little
Executive Vice President of Corporate Development & Strategy
Dr. Hans-Peter Stoll M.D., Ph.D.
Chief Clinical Officer
Dr. Avraham Matityahu Fischer M.D.
Senior Vice President of Medical Affairs & Innovation
Mr. Juan Lorenzo
Senior Vice President of Product Development
Dr. Yuval Hay Mika D.Sc, Ph.D.
GM & Chief Technology Officer of Bioelectronic Therapies
Mr. Bob Laughner
Senior Vice President of Regulatory & Quality
Mr. Mark Pomeranz
GM & Executive Vice President of Interventional Therapies
Mr. Darren R. Sherman
Founder, President, Chief Operating Officer & Director